Dec 30, 2024 7:00am EST Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug Namodenoson
Dec 04, 2024 7:00am EST 8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite’s Namodenoson Drug
Nov 11, 2024 7:00am EST Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial
Nov 04, 2024 7:08am EST Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia
Oct 18, 2024 9:06am EDT Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson
Oct 09, 2024 7:00am EDT FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer
Oct 07, 2024 7:00am EDT Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29
Sep 24, 2024 7:00am EDT Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis
Sep 16, 2024 7:00am EDT Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health
Aug 29, 2024 8:15am EDT Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies
